| Product NDC: | 0087-6633 |
| Proprietary Name: | VIDEX |
| Non Proprietary Name: | didanosine |
| Active Ingredient(s): | 10 mg/mL & nbsp; didanosine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | POWDER, FOR SOLUTION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0087-6633 |
| Labeler Name: | Bristol-Myers Squibb Company |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA020156 |
| Marketing Category: | NDA |
| Start Marketing Date: | 19911009 |
| Package NDC: | 0087-6633-41 |
| Package Description: | 1 BOTTLE in 1 CARTON (0087-6633-41) > 400 mL in 1 BOTTLE |
| NDC Code | 0087-6633-41 |
| Proprietary Name | VIDEX |
| Package Description | 1 BOTTLE in 1 CARTON (0087-6633-41) > 400 mL in 1 BOTTLE |
| Product NDC | 0087-6633 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | didanosine |
| Dosage Form Name | POWDER, FOR SOLUTION |
| Route Name | ORAL |
| Start Marketing Date | 19911009 |
| Marketing Category Name | NDA |
| Labeler Name | Bristol-Myers Squibb Company |
| Substance Name | DIDANOSINE |
| Strength Number | 10 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |